Horizon Pharma
Northbrook
About Horizon Pharma
Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 1,001 – 5,000
- Estimated revenue: $1M – $10M
- Total funding: $4.5B
- Funding stage: M&A
- Last round: Post-IPO Equity (Aug 2020)
- Ticker: nasdaq:HZNP
- Website: horizontherapeutics.com
- Phone: +353 1 772 2100
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/horizon-pharma-133899 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.